$APGE News

Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript

Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis - Slideshow

Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing

Truist Securities Maintains Hold on Apogee Therapeutics, Lowers Price Target to $81

BTIG Reiterates Buy on Apogee Therapeutics, Maintains $137 Price Target

Wedbush Maintains Outperform on Apogee Therapeutics, Raises Price Target to $135

Apogee Therapeutics Says Phase 2 APEX Trial Of Zumilokibart Met Primary And Secondary Endpoints; 65.9% Of Patients Achieved EASI‑75 In Moderate‑To‑Severe AD

Apogee Therapeutics Enters Strategic Financing Collaboration With Blackstone For Up To $1.3B In Non-Dilutive Capital For The Development And Commercialization Of Zumilokibart

Apogee Therapeutics (NASDAQ:APGE) Beats Q1 Estimates with Strong Cash Runway and Promising Clinical Progress

Apogee Therapeutics Q1 EPS $(1.06) Beats $(1.08) Estimate

Rothschild & Co Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $140

Mizuho Maintains Outperform on Apogee Therapeutics, Raises Price Target to $110

Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart Data

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

Apogee Therapeutics shares are trading higher. The company announced it priced its $350 million public offering of 5 million shares at $7.00 per share.

Apogee Therapeutics shares are trading higher. The company announced it priced its $350 million public offering of 5 million shares at $7.00 per share.

Reported Earlier, Apogee Therapeutics Prices $350M In Public Offering Of 5M Common Stock Shares Priced At $70.00 Each

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy